Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene discovery in bladder cancer progression using cDNA microarrays.

Marta Sanchez-Carbayo1, Nicholas D Socci, Juan Jose Lozano

  • 1Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. sanchezm@mskcc.org

The American Journal of Pathology
|July 24, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SECmeres outperform extracellular vesicles as potential blood RNA biomarkers for Alzheimer's disease.

Nature communications·2026
Same author

A Tumor-Promoting Inflammatory SPP1+ Macrophage-IL6-CRP Axis Drives Immune Dysfunction in Bladder Cancer.

Cancer discovery·2026
Same author

Author Correction: Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.

Nature genetics·2026
Same author

Humoral SARS-CoV-2 vaccine responses are durable in solid organ transplant recipients with and without HIV.

Vaccine·2025
Same author

Author Correction: An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.

Nature genetics·2025
Same author

An improved and economical LLE-LC/MS method for quantifying phosphatidylethanol: Identification and separation of isotopic cross-talk in clinical alcohol testing.

Clinical biochemistry·2025

This study identifies key gene expression changes in bladder cancer progression, revealing molecular biomarkers like p33ING1 that predict patient survival and inform targeted therapies for improved outcomes.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Bladder cancer progression involves complex gene expression alterations.
  • Understanding these changes is crucial for identifying diagnostic and prognostic markers.

Purpose of the Study:

  • To identify gene expression profiles associated with bladder cancer progression.
  • To discover molecular biomarkers for predicting clinical outcomes and therapeutic targets.

Main Methods:

  • Comparative gene expression profiling of early-stage and advanced bladder tumors using cDNA microarrays (17,842 genes).
  • Hierarchical clustering with bootstrapping and multidimensional analysis for tumor classification.
  • Differential gene expression analysis using t-tests, logistic regression, and support vector machines.

Related Experiment Videos

  • Validation of top molecular targets (Cytokeratin 20, neuropilin-2, p21, p33ING1) by immunohistochemistry on tissue microarrays (n=173).

    • Main Results:

    • Gene expression profiling successfully segregated bladder tumors based on stage and clinical outcome.
    • Identified differentially expressed genes, including Cytokeratin 20, neuropilin-2, p21, and p33ING1, associated with pathological stage, grade, and retinoblastoma (RB) expression.
    • p33ING1 expression significantly correlated with overall survival.
    • Overexpression of oncogenic DEK in superficial tumors and immune response genes like Cd86 antigen in invasive disease were noted.

    Conclusions:

    • Gene profiling is effective in classifying bladder tumors and predicting outcomes.
    • Identified novel molecular biomarkers and therapeutic targets for bladder cancer.
    • The findings provide insights into critical pathways involved in bladder cancer progression.